Skip to main content
. Author manuscript; available in PMC: 2020 May 8.
Published in final edited form as: Neuroepidemiology. 2019 May 8;53(1-2):100–107. doi: 10.1159/000500157

Table 2.

aPL positivity at baseline among 956 participants

Variable aPL positivity
n (%)
Overall aPL positivity 197 (20.6%)
 Anticardiolipin antibodies (aCL) 165 (17.3%)
  IgG 43 (4.5%)
  IgM 126 (13.2%)
 Antibodies to β2-glycoprotein I (anti-β2GPI) 87 (9.1%)
  IgG 26 (2.7%)
  IgM 65 (6.8%)
 Antiphosphatidyl-serine antibodies (aPS) 58 (6.1%)
  IgG 12 (1.3%)
  IgM 46 (4.8%)